Portola Pharmaceuticals Inc. (Nasdaq: PTLA) reported disappointing results from a Phase 3 APEX clinical trial of betrixaban to prevent blood clot in acute medically ill patients.
Disappointing study results for Portola Pharmaceuticals
March 24, 2016 at 12:56 PM EDT
